Etude des facteurs pronostiques de survie dans le carcinome hépatocellulaire traité par sorafénib : impact de la surface de graisse viscérale - Université de Lorraine Access content directly
Master Thesis Year : 2013

A single center experience of sorafenib in hepatocellular carcinoma patients : evaluation of prognostic factors, impact of visceral fat area and safety profile

Etude des facteurs pronostiques de survie dans le carcinome hépatocellulaire traité par sorafénib : impact de la surface de graisse viscérale

Abstract

OBJECTIVE : To retrospectively evaluate the tolerance and the prognostic factorsassociated with better outcome in patients treated with sorafenib for advanced orrefractory/relapsing intermediate hepatocellular carcinoma (HCC) in real-life clinicalpractice, including the specific influence of visceral fat area (VFA).METHODS : 68 HCC patients treated with sorafenib and followed in Hepato-gastroenterology department of Nancy Universitary Hospital from 2007 to 2012 were enrolled. VFA was retrospectively measured on one cross-sectional scan obtained at the umbilicus on CT scan performed within 1 year prior to sorafenib initiation. Tumour response was retrospectively evaluated according to mRECIST criteria. Overall survival (OS) and progression free survival (PFS) were determined. Safety data were collected.RESULTS: Median OS was 12.0 months and median PFS was 3.0 months. In multivariate analysis, a PS > 1, the presence of vascular invasion and high ASAT baseline levels were significantly associated with shorter OS (HR respectively of 2.41, 2.43 and 1.51). PS > 1, high ASAT baseline levels and a Child-Pugh score > B7 were independent predictive factors of shorter PFS (HR respectively of 1.51, 1.4 and 1.47). Semi-quantitative prognostic scores for OS and PFS were determined. Half of patients presented adverse events leading to definitive discontinuation of sorafenib. The most frequent adverse events were diarrhea (33.5%), fatigue (30.9%) and hand-foot syndrome reaction (23.5%).CONCLUSION : No impact of VFA on survival was identified. The developed semiquantitative prognostic scores could be useful to identify HCC patients who could take the most advantage from sorafenib therapy
Fichier principal
Vignette du fichier
BUMED_T_2013_SEIGNE_ANNE_LAURE.pdf (1.08 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01733900 , version 1 (14-03-2018)

Identifiers

  • HAL Id : hal-01733900 , version 1

Cite

Anne-Laure Seigne. Etude des facteurs pronostiques de survie dans le carcinome hépatocellulaire traité par sorafénib : impact de la surface de graisse viscérale. Sciences du Vivant [q-bio]. 2013. ⟨hal-01733900⟩
41 View
671 Download

Share

Gmail Facebook X LinkedIn More